PW Medtech GroupFRA:PWE -2.75%84 Days Payable is 46.07 as of Dec. 2025, which is 6% above its 10-year median of 43.51. GuruFocus rates FRA:PWE with a GF Score™ of 84/100 and a GF Value™ of €0.13. The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, PW Medtech Group ranks worse than 72.7% on this metric.
The historical rank and industry rank for PW Medtech Group's Days Payable or its related term are showing as below:
FRA:PWE'
s Days Payable Range Over the Past 10 Years
Min: 30.24 Med: 43.51 Max: 114.61
Current: 43.6
During the past 13 years, PW Medtech Group's highest Days Payable was 114.61. The lowest was 30.24. And the median was 43.51.
FRA:PWE's Days Payable is ranked worse than 72.7% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs FRA:PWE: 43.60
PW Medtech Group's Days Payable
increased
from Dec. 2024 (36.49) to Dec. 2025 (46.07).
It may suggest that PW Medtech Groupdelayed paying its suppliers.
PW Medtech Group Days Payable Related Terms
PW Medtech Group Days Payable Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PWE vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, PW Medtech Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's Days Payable distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PW Medtech Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PW Medtech Group (FRA:PWE) has a Days Payable of 46.07 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PW Medtech Group and its competitors. This is near median its historical median of 43.51. Over the past decade, PW Medtech Group's Days Payable has ranged from 30.24 to 114.61. According to the industry distribution chart, PW Medtech Group ranks #578 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 72.7%.
Is PW Medtech Group's Days Payable too high?
PW Medtech Group's current Days Payable of 46.07 is near median its 10-year median of 43.51. Over the past 10 years, this metric has ranged from a low of 30.24 to a high of 114.61. The Medical Devices & Instruments industry median Days Payable is 68.07. PW Medtech Group's value of 46.07 is 32.3% below this industry median. Based on the distribution chart, PW Medtech Group ranks #578 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PW Medtech Group has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #578 out of 795 companies for Days Payable. This places PW Medtech Group in the lower half of its industry. The industry median Days Payable is 68.07. PW Medtech Group's value of 46.07 is 32.3% below this benchmark. Historically, PW Medtech Group's own Days Payable has ranged from 30.24 to 114.61 over the past decade. While the company's 10-year median is 43.51 vs. the industry median of 68.07, PW Medtech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current Days Payable of 46.07 is 32.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PW Medtech Group and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current Days Payable is 46.07, which is near median its own 10-year median of 43.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
PW Medtech Group (FRA:PWE) has a current Days Payable of 46.07. The stock's GF Value™ is €0.13, compared to a current price of €0.11 — trading 18.5% below its estimated fair value. The current Days Payable is 46.07, which is near median its 10-year median of 43.51 and 32.3% below the Medical Devices & Instruments industry median of 68.07. PW Medtech Group's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current Days Payable is 46.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.11 is trading 18.5% below its estimated GF Value™ of €0.13.
Key valuation signals for FRA:PWE:
Days Payable: 46.07 (near median its 10-year median of 43.51)
GF Value™: €0.13 vs. price of €0.11 (18.5% below fair value)
Industry Position: 32.3% below the Medical Devices & Instruments median (#578 of 795)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
84GF Score
Get the complete analysis for FRA:PWE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
